Shares of C R Bard Inc (NYSE:BCR) have earned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $332.00.
A number of research analysts have recently commented on the company. Cowen reiterated a “hold” rating and issued a $317.00 price objective on shares of C R Bard in a report on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C R Bard in a report on Thursday, October 26th. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays increased their price objective on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Finally, Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective on the stock in a report on Tuesday, December 26th.
In related news, VP John A. Deford sold 14,107 shares of the company’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $333.48, for a total value of $4,704,402.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jim C. Beasley sold 15,044 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $332.00, for a total value of $4,994,608.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,546 shares of company stock valued at $10,826,150. Insiders own 0.80% of the company’s stock.
C R Bard has a 1-year low of $223.02 and a 1-year high of $337.73. The firm has a market cap of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.